Loading company
$2.85-1.9%Nov 10 close
Figures through June 30, 2026, from the 6-K filed August 17, 2026
Past performance
- 1W
- +1.1%
- 1M
- -10.4%
- 3M
- -21.3%
- 6M
- -4.0%
- 1Y
- -61.5%
$2.85-1.9%Nov 10 close
Figures through June 30, 2026, from the 6-K filed August 17, 2026
From the company’s own 6-K filing.
Nasus Pharma Ltd has no earnings call transcript available.
“Nasus has made enormous progress in its clinical programs in the first six months of 2026, and we believe it is well positioned to advance to NS002 and NS003 toward key milestones in the second half of the year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Nasus Pharma Ltd. (NYSE: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Nasus Pharma Ltd filed on August 17, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.